Early research (Phase 1)Study completedNCT04950764
What this trial is testing
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Who this might be right for
Primary Biliary CholangitisCompensated CirrhosisHepatic Impairment
Gilead Sciences 24